Evotec Selects Navan's AI-Powered Platform to Unify Global Travel and Expense Management
核心洞察
Evotec, a global drug discovery and development company, has selected Navan (搜索) to manage its complete corporate travel and expense program across its top global markets.
The rollout spans Germany, the UK, U.S., Italy, and France, replacing a patchwork of disparate tools and manual offline processes with one unified platform.
The transition aims to enhance operational excellence by automating reconciliation directly from the point of swipe and reducing manual expense reporting.
Evotec, the global drug discovery and development company, has selected Navan (搜索)'s AI-powered business travel and expense platform to manage its complete corporate Travel and Expense (T&E) program across its top global markets, the companies announced on July 23, 2026.
The partnership marks a significant operational upgrade for Evotec, which had historically managed T&E independently across different countries, leaving employees to navigate a patchwork of different tools and manual offline processes. As part of its broader focus on operational excellence, Evotec is now streamlining these processes through one unified, easy-to-use platform designed to support consistency, transparency, and efficiency.
"Simplifying processes and strengthening operational excellence while enabling our employees with efficient tools are key priorities for Evotec," said Kay Prätorius, VP Procurement at Evotec. "Transitioning to the single, intuitive Navan (搜索) platform will enhance the overall user experience, providing real-time visibility and control over our global travel and expense activities."
Rollout Across Five Key Markets
Evotec is deploying Navan (搜索) across Germany, the UK, U.S., Italy, and France. The implementation aims to streamline the user experience and reduce the need for manual entry by automating reconciliation directly from the point of swipe. This automation is expected to eliminate much of the manual expense reporting burden that previously fell on employees across the organization.
Zahir Abdelouhab, SVP, Enterprise Sales, EMEA at Navan (搜索), commented on the efficiency gains typically observed when organizations modernize their T&E systems. "Evotec is taking an important step in further streamlining and standardizing its processes and Navan is supporting this by bringing greater clarity and simplicity to travel and expense management, supporting teams in focusing on their core work," Abdelouhab said.
Operational Context for a Global R&D Organization
Evotec operates as a life science company pioneering drug discovery and development, integrating breakthrough science with AI-driven innovation and advanced technologies. The company's expertise spans small molecules, biologics, cell therapies, and associated modalities, supported by proprietary platforms including Molecular Patient Databases, PanOmics, and iPSC-based disease modeling.
With a global team of more than 4,500 experts operating from sites in Europe and the U.S., Evotec works with all Top 20 Pharma companies, over 800 biotechs, academic institutions, and healthcare stakeholders. The company maintains a portfolio of over 100 proprietary R&D assets, most of them co-owned, focusing on key therapeutic areas including oncology, cardiovascular and metabolic diseases, neurology, and immunology.
The transition to Navan (搜索)'s unified platform represents a practical step toward reducing administrative friction across this extensive global operation, allowing scientific and operational teams to dedicate more time to their core drug discovery and development mission.